NasdaqHealth CarePharmaceutical PreparationsAUSTIN, TX

Faeth Therapeutics, Inc. FTH

Ask your AI

Estimated market cap $259.21M25.84M shares, shares as of Oct 30, 2026CIK 1829802

Insider trades, 12 mo

49 buys · 45 sells

$2.28M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

19.3% of shares · 13 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Faeth Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 3, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Faeth Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

94 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jul 1, 2026. Insiders have two business days to file.

Recent insider trades

Brian C. Stephenson Chief Financial Officer	Jul 1 Form 4 ↗	Buy	+$103.0K 4,400 sh @ $23.40	-58.8%
Brian C. Stephenson Chief Financial Officer	Jul 1 Form 4 ↗	Buy	+$14.5K 600 sh @ $24.22	-58.8%
Brian C. Stephenson Chief Financial Officer	Jun 30 Form 4 ↗	Buy	+$106.3K 4,255 sh @ $24.98	-60.9%
Brian C. Stephenson Chief Financial Officer	Jun 30 Form 4 ↗	Buy	+$39.1K 1,638 sh @ $23.88	-60.9%
Brian C. Stephenson Chief Financial Officer	Jun 30 Form 4 ↗	Buy	+$43.8K 1,910 sh @ $22.95	-60.9%

All FTH insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

4.99M shares

41 funds report FTH. Values checked against market prices.

Funds own 54% of shares (Q2 2026)

44 funds hold the stock.

Q3 2026: 19% · 5,560 of ~8,900 funds reported so far

Q1 20250.1%
Q2 20255.5%
Q3 20253.9%
Q4 20253.8%
Q2 202654%
Q3 2026 (so far)19%

Q3 2026. 22 new, 13 added to, 3 trimmed, 26 exited since Q2 2026.

Top 13F holders
#
1	Vanguard Capital Management LLC 13F ↗	951,721	$28.3M	+9309.0%
2	Vivo Capital, LLC 13F ↗	844,576	$25.1M	+17.0%
3	BlackRock, Inc. 13F ↗	414,823	$12.3M	+12093.5%
4	UBS Group AG 13F ↗	369,972	$11.0M	+1617.5%
5	Franklin Templeton Inc 13F ↗	517,982	$10.4M	+4.7%
6	Candriam S.C.A. 13F ↗	319,663	$9.5M	New
7	State Street Corp 13F ↗	311,427	$9.3M	New
8	Geode Capital Management, LLC 13F ↗	231,865	$6.9M	+1486.4%
9	Affinity Asset Advisors, LLC 13F ↗	144,404	$4.3M	unchanged
10	Silverarc Capital Management, LLC 13F ↗	124,098	$3.7M	New

Download CSV Every fund that holds FTH, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Faeth Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Faeth Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q1 2025	1	—	826	$6,507
Q2 2025	10	+9	69,928	$600.0K
Q3 2025	9	-1	49,367	$466.5K
Q4 2025	10	+1	48,247	$514.8K
Q1 2026	30	+20	2.29M	$72.2M
Q2 2026	45	+15	14.07M	$333.8M
Q3 2026	41	-4	4.99M	$143.5M

Each point is a quarter-end, from Q1 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (81728A207). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-20 on Jun 17, 2025): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes12 in 12 mo 8-K events5 in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 8 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Faeth Therapeutics, Inc.
Address: 701 TILLERY STREET #12 #1010, AUSTIN, TX 78702
Phone: 512-200-2982
Fiscal year ends: Dec 31
Filer category: emerging growth company
Incorporated in: DE
Listed as: FTH (Nasdaq)
Former names: Sensei Biotherapeutics, Inc. (until 2026)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$10.03−$0.62 (−5.82%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $10.03 · High $22.05Nov 13, 2026

Aug 13, 2026Low $10.03 · High $40.05Nov 13, 2026

Nov 13, 2025Low $7.89 · High $40.05Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.